Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

23 Jun 2023

Abstract excerpt

Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair. PARPi takes PARP as a target to kill tumor cells, especially for tumors with homologous recombination (HR) dysfunction. Currently, PARPi has been widely used in clinical practice,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37426808
DOI: 10.3389/fphar.2023.1164395

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerPMID 37426808Read ↗

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerSemantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA MutationsSemantic proximity Read ↗

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read ↗

The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancerSemantic proximity Read ↗

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current statusSemantic proximity Read ↗

A review on mechanisms of resistance to PARP inhibitorsSemantic proximity Read ↗

Therapeutic applications of PARP inhibitors in ovarian cancerSemantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

Mechanism of PARP inhibitor resistance and potential overcoming strategiesSemantic proximity Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.